Business Leaders

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
HomeAll NewsMost read newsBusiness Leaders Biography
Portrait de Daniel O'Day
Age : 57
Public asset : 15,003,524 USD
Country of residence : Unknown
Linked companies : Gilead Sciences, Inc. - Galapagos NV

Biography of Daniel O'Day 
Mr. Daniel P. O'Day is a Chairman & Chief Executive Officer at Gilead Sciences, Inc. He is on the Board of Directors at Galapagos NV, Flatiron Health, Inc., Pharmaceutical Manufacturers Association of America, Pharmaceutical Research & Manufacturers of America and Shanghai Roche Pharmaceuticals Ltd. Mr. O'Day was previously employed as a President & Chief Executive Officer by Roche Molecular Systems, Inc., a General Manager by Roche A/S Medicinalvarer OG Kemikalier, a Chief Operating Officer by Roche Diagnostics A/S, a Head-Business Unit, Arthritis & Respiratory by Roche Pharma Schweiz AG, a Chief Executive Officer by Roche Pharmaceuticals, Inc., a Head-Corporate Planning by Roche Diagnostics KK, and a CEO-Roche Pharmaceuticals by Roche Holding AG. He also served on the board at Foundation Medicine, Inc., Chugai Pharmaceutical Co., Ltd., Genentech, Inc. and Roche Diagnostics GmbH. He received his undergraduate degree from Georgetown University and an MBA from The Trustees of Columbia University in The City of New York.


Current positions of Daniel O'Day 
Holdings of Daniel O'Day 
Daniel O'Day : Personal Network 
Most Read News 
08/06ELON MUSK : Musk says Twitter deal should go ahead if it provides proof of real accounts
RE
08/09ELON MUSK : Elon Musk sells 7.92 million Tesla shares worth $6.9 billion - SEC filing
RE
08/12MASAYOSHI SON : With Alibaba stake cut, SoftBank's Son cools toward China tech
RE
08/04JACK DORSEY : Dorsey-led Block posts loss for second quarter
RE
08/02ELON MUSK : Twitter queries banks on Musk's attempts to undermine $44 billion deal
RE
08/13ANSHU JAIN : Former Deutsche Bank co-CEO Anshu Jain dies - Bloomberg News
RE
08/01DAVID EINHORN : Einhorn's Greenlight takes stake in Twitter - letter
RE
08/02STEPHEN KING : Horror author Stephen King says in publishing trial that consolidation hurts competition
RE
08/01STEPHEN KING : Stephen King goes to bat for U.S. gov't in case against book publishing mega-merger
RE
08/04ELON MUSK : Twitter rejects Musk's claims that he was hoodwinked
RE
More news


© 2022 People and Ownership :   
Daniel O'Day : Connections 


Latest news about Daniel O'Day 
08/02TRANSCRIPT : Gilead Sciences, Inc., Q2 2022 Earnings Call, Aug 02, 2022
CI
06/15TRANSCRIPT : Gilead Sciences, Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-15-2022 11:20 AM
CI
06/04Gilead drug modestly delays breast cancer progression in late-stage trial
RE
06/04Gilead drug modestly delays breast cancer progression in late-stage trial
RE
04/28TRANSCRIPT : Gilead Sciences, Inc., Q1 2022 Earnings Call, Apr 28, 2022
CI
More news